FDA gathers information for plans to regulate nanoscale drugs

摘要

A potential wave of nanoscale drug products is expected to surge through FDA in the coming years.rnFDA officials are gathering information to prepare for how to regulate these future nanoscale drugs. A public meeting on nanotechnology, held September 8 in Rockville, Maryland, brought to light varying schools of thought on how to approach the subject.rnFrank Torti, FDA's chief scientist, stressed to attendees that his agency cannot solve these problems alone and that stakeholder input will be vital to setting regulations for nanoscale drugs.